
[008] In some examples, the combination comprises from about 5 mg to about 100 mg of the compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof. In some examples, the combination comprises about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, or about 50 mg of the compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof.

[009] In some examples, the EGFR TK inhibitor is a small molecule compound, a nucleic acid, a peptide, a protein, an antibody, a peptibody, a diabody, a minibody, a single-chain variable fragment (ScFv), or a fragment or variant thereof. In some examples, the EGFR TK inhibitor is selected from erlotinib, afatinib, gefitinib, osimertinib, dacomitinib, icotinib, rociletinib, olmutinib, tarloxotinib, TAK-788, amivantamab (JNJ-6372), or AC0010. In some examples, the EGFR TK inhibitor is osimertinib.

[0010] Provided herein is a pharmaceutical composition comprising a combination as described herein and a pharmaceutically acceptable excipient.

[0011] Provided herein are methods for preventing and/or treating non-receptor protein tyrosine phosphatase-mediated or dependent diseases or conditions. In some examples, provided herein is a method of treating cancer in a subject in need thereof,


comprising administering to the patient a combination comprising a therapeutically effective amount of a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof:



Formula (Ia),

and a therapeutically acceptable amount of an EGFR TK inhibitor.


[0011a] In another aspect, provided herein is use of a combination in the manufacture of a medicament for treating cancer, wherein the combination comprises a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof:



(Ia)

and an EGFR TK inhibitor.

[0011b] In another aspect, provided herein is a combination comprising a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof:



(Ia)

and an EGFR TK inhibitor, for use in therapy.

[0012] In some examples, the compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, is administered to said patient in need from about 5 mg/kg to about 25 mg/kg. In some examples, the compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof is administered to said patient in need at about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, or about 25 mg/kg.


[0013] In some examples, the EGFR TK inhibitor is a small molecule compound, a nucleic acid, a peptide, a protein, an antibody, a peptibody, a diabody, a minibody, a single-chain variable fragment (ScFv), or a variant thereof. In some examples, the EGFR TK inhibitor is selected from erlotinib, afatinib, gefitinib, simertinib, dacomitinib, icotinib, rociletinib, olmutinib, tarloxotinib, TAK-788, amivantamab (JNJ-6372), or AC0010. In some examples, the EGFR TK inhibitor is Osimertinib.

[0014] In some examples, the method comprises administering the compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and the EGFR TK inhibitor simultaneously or sequentially. In some examples, the method comprises administering the compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and the EGFR TK inhibitor to the patient as a regimen. In some examples, the method comprises administering a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and an EGFR TK inhibitor to said patient orally or as an intraperitoneal injection. In some examples, administration is by intravenous injection (I.V). In some examples, the method comprises administering a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and an EGFR TK inhibitor to the patient daily. In some examples, the method comprises administering a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and an EGFR TK inhibitor QD, BID, or TID.

[0015] In some examples, the patient is treatment naïve. In some examples, the method comprises administering a compound of Formula (Ia), or a pharmaceutically acceptable salt of solvate thereof; and an EGFR TK inhibitor to said patient as a first line therapy. In some

WHAT IS CLAIMED IS:


1. A combination comprising a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof:



(Ia),

and an EGFR TK inhibitor (epidermal growth factor receptor tyrosine kinase inhibitor).

2. The combination of claim 1, wherein said combination comprises from 5 mg to 100 mg of said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof.
3. The combination of claim 1, wherein said combination comprises 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, or 50 mg of said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof.
4. The combination of any one of claims 1-3, wherein said EGFR TK inhibitor is a small molecule compound, a nucleic acid, a peptide, a protein, an antibody, a peptibody, a diabody, a minibody, a single-chain variable fragment (ScFv), or a variant thereof.
5. The combination of any one of claims 1-3, wherein said EGFR TK inhibitor is selected from erlotinib, afatinib, gefitinib, osimertinib, dacomitinib, icotinib, rociletinib, olmatinib, tarloxotinib, TAK-788, amivantamab (JNJ-6372), or AC0010.
6. The composition of claim 5, wherein said EGFR TK inhibitor is osimertinib.
7. Use of a combination in the manufacture of a medicament for treating cancer, wherein the combination comprises a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof:




(Ia)

and an EGFR TK inhibitor.

8. The use of claim 7, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, is to be administered from 5 mg/kg to 25 mg/kg.
9. The use of claim 7, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof is to be administered at 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, or 25 mg/kg.
10. The use of any one of claims 7-9, wherein said EGFR TK inhibitor is a small molecule compound, a nucleic acid, a peptide, a protein, an antibody, a peptibody, a diabody, a minibody, a single-chain variable fragment (ScFv), or a variant thereof
11. The use of any one of claims 7-9, wherein said EGFR TK inhibitor is selected from erlotinib, afatinib, gefitinib, osimertinib, dacomitinib, icotinib, rociletinib, olmatinib, tarloxotinib, TAK-788, amivantamab (JNJ-6372), or AC0010.
12. The use of claim 11, wherein said EGFR TK inhibitor is Osimertinib.
13. The use of any one of claims 7-12, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and said EGFR TK inhibitor are to be administered simultaneously or sequentially.
14. The use of any one of claims 7-13, wherein said cancer is squamous cell carcinoma, nonsquamous cell carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer, melanoma, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, head and neck cancer, urothelial cancer, breast cancer, prostate cancer, glioblastoma, colorectal cancer, pancreatic cancer, lymphoma, leiomyosarcoma, liposarcoma, synovial sarcoma, or malignant peripheral sheath tumor (MPNST).
15. The use of any one of claims 7-14, wherein the medicament is for treating cancer in a patient that is treatment naïve.
16. The use of any one of claims 7-14, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt of solvate thereof; and said EGFR TK inhibitor are to be administered as a first line therapy.
17. The use of any one of claims 7-14, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and said EGFR TK inhibitor are to be administered as a second, third, fourth, fifth, or sixth line of treatment.
18. The use of any one of claims 7-14, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and said EGFR TK inhibitor are to be administered following treatment with at least one anti-cancer therapy, wherein said anti-

cancer therapy is chemotherapy, radiotherapy, surgery, targeted therapy, immunotherapy, or a combination thereof.

19. The use of any one of claims 7-14, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and said EGFR TK inhibitor are to be administered to a patient who has failed another EGFR TK inhibitor therapy.
20. The use of any one of claims 7-19, wherein said cancer is resistant to at least one anti-cancer agent.
21. The use of any one of claims 7-20, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and said EGFR TK inhibitor are to be administered as a regimen.
22. The use of any one of claims 7-21, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and said EGFR TK inhibitor are to be administered orally or by intraperitoneal injection.
23. The use of any one of clams 7-22, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and said EGFR TK inhibitor are to be administered daily.
24. The use of claim 23, wherein said compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof; and said EGFR TK inhibitor are to be administered QD, BID, or TID.
25. The use of any one of claims 7-24, wherein treating cancer inhibits metastasis of said cancer.
26. The use of any one of claims 7-24, wherein treating cancer prolongs the time to disease progression of said cancer.
27. The use of any one of claims 7-24, wherein treating cancer prolongs the survival.
28. The use of any one of claims 7-24, wherein treating cancer increases progression-free survival.
29. The use of any one of claims 7-24, wherein treating cancer reduces tumor or tumor burden.
30. A combination comprising a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof:



(Ia)

and an EGFR TK inhibitor, for use in therapy.